https://www.pharmaradar360.com/article/wall-street-thinks-this-biotech-stock-can-soar-45-here-s-why-analysts-are-right-868612ab5086bdedPharma Surgeen2026-07-02T11:06:48.000ZWall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.https://www.pharmaradar360.com/article/thermo-fisher-to-back-arcturus-nasdaq-arct-arct-032-phase-3-and-manufacturing-cc37e9d7b209c515Pharma Surgeen2026-07-02T11:06:24.000ZThermo Fisher to back Arcturus (NASDAQ: ARCT) ARCT-032 Phase 3 and manufacturinghttps://www.pharmaradar360.com/article/china-ai-drug-design-deals-swell-as-us-scrutiny-mounts-25460db6c16037caPharma Surgeen2026-07-02T11:00:10.000ZChina AI drug-design deals swell as US scrutiny mountshttps://www.pharmaradar360.com/article/rare-and-imported-pathogens-laboratory-ripl-user-manual-9019c0801efa285ePharma Surgeen2026-07-02T11:00:01.000ZRare and Imported Pathogens Laboratory (RIPL): user manualhttps://www.pharmaradar360.com/article/veraxa-advances-lead-cancer-drug-toward-manufacturing-work-with-atum-e50939384e0a2961Pharma Surgeen2026-07-02T11:00:00.000ZVERAXA advances lead cancer drug toward manufacturing work with ATUMhttps://www.pharmaradar360.com/article/arcturus-taps-thermo-fisher-to-make-its-cystic-fibrosis-therapy-d47dedd36ac9c659Pharma Surgeen2026-07-02T11:00:00.000ZArcturus taps Thermo Fisher to make its cystic fibrosis therapyhttps://www.pharmaradar360.com/article/tenax-to-present-level-trial-data-at-esc-congress-before-august-results-41f88e0d13e34b76Pharma Surgeen2026-07-02T11:00:00.000ZTenax to present LEVEL trial data at ESC Congress before August resultshttps://www.pharmaradar360.com/article/tenax-therapeutics-announces-late-breaking-presentation-of-level-clinical-trial-5412b80db22ab923Pharma Surgeen2026-07-02T11:00:00.000ZTenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026https://www.pharmaradar360.com/article/podcast-hlth-europe-and-bio-key-trends-rundown-337303b01579b413Pharma Surgeen2026-07-02T10:58:08.000ZPodcast: HLTH Europe and BIO key trends rundownhttps://www.pharmaradar360.com/article/wall-street-thinks-this-biotech-stock-can-soar-45-here-s-why-analysts-are-right-0f052de59c1aa164Pharma Surgeen2026-07-02T10:53:43.000ZWall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.https://www.pharmaradar360.com/article/analysis-50-cut-in-danish-pharma-production-could-cost-30-000-jobs-9d605be0cc93f389Pharma Surgeen2026-07-02T10:43:07.000ZAnalysis: 50% cut in Danish pharma production could cost 30,000 jobshttps://www.pharmaradar360.com/article/fda-approved-cannabis-is-coming-operators-should-prepare-now-5421ff5c3be320a8Pharma Surgeen2026-07-02T10:33:33.000ZFDA-approved cannabis is coming. Operators should prepare now.https://www.pharmaradar360.com/article/halfway-into-the-year-biotech-is-booming-4ad98a2294653004Pharma Surgeen2026-07-02T10:33:10.000ZHalfway into the year, biotech is boominghttps://www.pharmaradar360.com/article/adragos-and-towa-to-produce-1-5-billion-tablets-a-year-f7004863d35e1305Pharma Surgeen2026-07-02T10:32:25.000ZAdragos and Towa to Produce 1.5 Billion Tablets a Yearhttps://www.pharmaradar360.com/article/shanghai-fudan-zhangjiang-bio-pharmaceutical-subscribes-structured-deposit-produ-1313e3a1786dc08ePharma Surgeen2026-07-02T10:27:35.000ZShanghai Fudan-Zhangjiang Bio-Pharmaceutical Subscribes Structured Deposit Product With Amount Of RMB330 MLNhttps://www.pharmaradar360.com/article/an-extra-229-000-deaths-is-that-the-cost-of-us-uk-drugs-deal-ded292d3a9c13fbePharma Surgeen2026-07-02T10:27:29.000ZAn extra 229,000 deaths: Is that the cost of US-UK drugs deal?https://www.pharmaradar360.com/article/us-launches-security-probe-five-pharma-giants-doing-clinical-trials-in-china-bf01c28ba3004ff0Pharma Surgeen2026-07-02T10:08:57.000ZUS launches security probe five pharma giants doing clinical trials in Chinahttps://www.pharmaradar360.com/article/realistic-timelines-for-pharma-manufacturing-reshoring-4499d498dc4fc84fPharma Surgeen2026-07-02T10:07:30.000ZRealistic Timelines for Pharma Manufacturing Reshoringhttps://www.pharmaradar360.com/article/ipsen-to-buy-swiss-biotech-memo-in-deal-that-could-top-800-million-73876289c22bac33Pharma Surgeen2026-07-02T09:57:40.000ZIpsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Millionhttps://www.pharmaradar360.com/article/tracking-cathie-wood-major-circle-accumulation-and-biotech-cluster-build-up-trim-5a2141d13eb1b68bPharma Surgeen2026-07-02T09:34:59.000ZTracking Cathie Wood: Major Circle Accumulation and Biotech Cluster Build-Up, Trimming Alibaba and Medical Devicehttps://www.pharmaradar360.com/article/abivax-shares-continue-climbing-after-biotech-firm-moves-to-bolster-balance-shee-e082d08952be37f3Pharma Surgeen2026-07-02T09:25:00.000ZAbivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheethttps://www.pharmaradar360.com/article/takeda-insilico-strike-ai-drug-discovery-deal-worth-up-to-600-million-8a76d8e84b7c667aPharma Surgeen2026-07-02T09:22:00.000ZTakeda, Insilico Strike AI Drug-Discovery Deal Worth Up to $600 Millionhttps://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-march-2026-f6bcfb810bad2e74Pharma Surgeen2026-07-02T09:11:07.000ZAdult social care client level data, England: quarterly update to March 2026https://www.pharmaradar360.com/article/new-data-strengthen-cemdisiran-case-in-generalized-mg-e8cb98717488cc34Pharma Surgeen2026-07-02T09:09:55.000ZNew data strengthen cemdisiran case in generalized MGhttps://www.pharmaradar360.com/article/fe68bc0b69958ecaPharma Surgeen2026-07-02T09:02:37.000ZΠΡΟΚΗΡΥΞΗ ΠΛΗΡΩΣΗΣ ΘΕΣΕΩΝhttps://www.pharmaradar360.com/article/can-fite-to-test-namodenoson-in-pancreatic-cancer-d5955ad87e627e35Pharma Surgeen2026-07-02T09:02:20.000ZCan-Fite to test namodenoson in pancreatic cancerhttps://www.pharmaradar360.com/article/china-s-cspc-pharmaceutical-group-to-partner-with-astrazeneca-for-renal-disease-03b24634f4a67ca2Pharma Surgeen2026-07-02T08:55:31.000ZChina's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drughttps://www.pharmaradar360.com/article/lord-mann-review-on-antisemitism-and-other-forms-of-racism-in-the-nhs-7b9c2ee5668e8aacPharma Surgeen2026-07-02T08:54:16.000ZLord Mann review on antisemitism and other forms of racism in the NHShttps://www.pharmaradar360.com/article/medicines-eligible-for-northern-ireland-mhra-authorised-route-ea4846a98bf6c2a7Pharma Surgeen2026-07-02T08:51:10.000ZMedicines eligible for Northern Ireland MHRA Authorised Routehttps://www.pharmaradar360.com/article/safeguarding-uk-human-genomic-data-db7284ae2e26255dPharma Surgeen2026-07-02T08:44:54.000ZSafeguarding UK human genomic datahttps://www.pharmaradar360.com/article/glenmark-initiates-phase-3-trial-of-1-billion-cancer-buyout-trastuzumab-rezeteca-d24451c9ec4fce14Pharma Surgeen2026-07-02T08:42:04.000ZGlenmark initiates Phase 3 trial of $1 billion Cancer buyout Trastuzumab rezetecanhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-enters-collaboration-option-license-agreement-with-astrazene-6c9836bc12282393Pharma Surgeen2026-07-02T08:35:45.000ZCSPC Pharmaceutical Enters Collaboration, Option & License Agreement With Astrazeneca For siRNA Drugshttps://www.pharmaradar360.com/article/research-mhra-data-requirements-to-support-regulatory-decision-making-9c0cc286a346a7d3Pharma Surgeen2026-07-02T08:34:28.000ZResearch: MHRA data requirements to support regulatory decision makinghttps://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962cePharma Surgeen2026-07-02T08:30:07.000ZHigh consequence infectious disease: country specific riskhttps://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-07-02T08:30:07.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/sexually-transmitted-infections-london-data-927003b4155f03a8Pharma Surgeen2026-07-02T08:30:06.000ZSexually transmitted infections: London datahttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-b306771583db51dfPharma Surgeen2026-07-02T08:30:05.000ZRespiratory syncytial virus (RSV) older adults vaccination coverage in Englandhttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-e72ee03f6bc9d959Pharma Surgeen2026-07-02T08:30:05.000ZRespiratory syncytial virus (RSV) maternal vaccination coverage in Englandhttps://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-surveillance-reports-2025-to-2026-season-1192c065abd24222Pharma Surgeen2026-07-02T08:30:05.000ZNational norovirus and rotavirus surveillance reports: 2025 to 2026 seasonhttps://www.pharmaradar360.com/article/pre-release-access-lists-national-norovirus-and-rotavirus-surveillance-reports-f8340eaf52659afdPharma Surgeen2026-07-02T08:30:05.000ZPre-release access lists: National norovirus and rotavirus surveillance reportshttps://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-1b4c313e4093d4bbPharma Surgeen2026-07-02T08:30:05.000ZAdult social care client level data, England: quarterly updatehttps://www.pharmaradar360.com/article/borderline-products-how-to-tell-if-your-product-is-a-medicine-ce4e68ea226f4c9cPharma Surgeen2026-07-02T08:27:17.000ZBorderline products: how to tell if your product is a medicinehttps://www.pharmaradar360.com/article/decision-human-medicines-register-of-electronic-export-certificates-86062f304e916685Pharma Surgeen2026-07-02T08:24:22.000ZDecision: Human medicines: register of electronic export certificateshttps://www.pharmaradar360.com/article/ia-global-asset-management-inc-purchases-91-026-shares-of-teva-pharmaceutical-in-ed3e4304ef77b239Pharma Surgeen2026-07-02T08:22:07.000ZiA Global Asset Management Inc. Purchases 91,026 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/bii-takes-next-step-in-its-european-expansion-joins-new-italy-focused-venture-fu-882656ce46f9695aPharma Surgeen2026-07-02T08:19:00.000ZBII takes next step in its European expansion: Joins new Italy-focused venture fundhttps://www.pharmaradar360.com/article/top-10-sustainable-pharmaceutical-companies-573d0588902be79ePharma Surgeen2026-07-02T08:08:42.000ZTop 10: Sustainable Pharmaceutical Companieshttps://www.pharmaradar360.com/article/device-name-non-sterile-folded-gauze-yancheng-zaichuang-medical-supplies-co-ltd-a4989f9f74481525Pharma Surgeen2026-07-02T07:59:55.000ZΑνάκληση από την αγορά των προϊόντων με Device name: «Non-sterile folded gauze», της κατασκευάστριας εταιρείας YANCHENG ZAICHUANG MEDICAL SUPPLIES CO LTD (Κίνας) (Εξουσ. Αντιπρ. για την Ε.Ε. MedPath GmbH (Γερμανία)), τα οποία συνοδεύονται από παραποιημένη δήλωση συμμόρφωσης του κατασκευαστή.https://www.pharmaradar360.com/article/glenmark-advances-multi-country-phase-3-trial-of-trastuzumab-rezetecan-in-platin-65091022136350aaPharma Surgeen2026-07-02T07:18:47.000ZGlenmark Advances Multi-Country Phase 3 Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancerhttps://www.pharmaradar360.com/article/glenmark-advances-multi-country-phase-3-clinical-trial-of-trastuzumab-rezetecan-6bb4c5d02b7fd2f2Pharma Surgeen2026-07-02T07:15:50.000ZGlenmark advances multi-country phase 3 clinical trial of Trastuzumab rezetecan in PROChttps://www.pharmaradar360.com/article/platform-technologies-could-drive-korean-biotech-rebound-in-h2-analyst-59b9f8fed4c5911bPharma Surgeen2026-07-02T07:15:44.000ZPlatform technologies could drive Korean biotech rebound in H2: analysthttps://www.pharmaradar360.com/article/biotech-investor-pumps-the-brakes-on-ai-drug-discovery-88d76ca530f3fd4cPharma Surgeen2026-07-02T06:53:28.000ZBiotech Investor Pumps the Brakes on AI Drug Discoveryhttps://www.pharmaradar360.com/article/the-future-of-biotech-bridgebio-ionis-and-biomarin-are-worth-watching-f3be70d02109e89fPharma Surgeen2026-07-02T06:39:04.000ZThe Future of Biotech? BridgeBio, Ionis and BioMarin Are Worth Watchinghttps://www.pharmaradar360.com/article/divarasib-iii-krascendo1-3c6e741c25d0693aPharma Surgeen2026-07-02T06:30:00.000Zロシュ社によるdivarasibに関する発表について（第III相Krascendo1試験結果）https://www.pharmaradar360.com/article/roche-s-announcement-regarding-divarasib-announcement-of-phase-iii-krascendo1-st-611cfbc63452a5c0Pharma Surgeen2026-07-02T06:30:00.000ZRoche’s Announcement Regarding divarasib (Announcement of Phase III Krascendo1 Study Results)https://www.pharmaradar360.com/article/ad-hoc-announcement-pursuant-to-art-53-lr-roche-s-divarasib-shows-superiority-in-255702641dea2184Pharma Surgeen2026-07-02T05:00:00.000Z[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancerhttps://www.pharmaradar360.com/article/telix-clears-fda-protocol-review-for-prostate-cancer-trial-expansion-133e34d72ff7e03fPharma Surgeen2026-07-02T04:12:25.000ZTelix clears FDA protocol review for prostate cancer trial expansionhttps://www.pharmaradar360.com/article/glenmark-advances-phase-3-cancer-trial-shares-edge-higher-7e578a6d72d1a111Pharma Surgeen2026-07-02T04:11:45.000ZGlenmark Advances Phase 3 Cancer Trial; Shares Edge Higherhttps://www.pharmaradar360.com/article/telix-pharmaceuticals-aligns-with-fda-on-phase-3-trial-6728f3023b91ac23Pharma Surgeen2026-07-02T03:47:33.000ZTelix Pharmaceuticals aligns with FDA on Phase 3 trialhttps://www.pharmaradar360.com/article/glenmark-pharma-wins-india-s-1st-phase-3-approval-for-trastuzumab-rezetecan-canc-1854556ff44ce431Pharma Surgeen2026-07-02T03:39:12.000ZGlenmark Pharma Wins India's 1st Phase 3 Approval for Trastuzumab Rezetecan Cancer Trialhttps://www.pharmaradar360.com/article/ecowaste-coalition-echoes-fda-b-e-a-t-reminders-on-musical-toys-2a3d5dd49c522bd3Pharma Surgeen2026-07-02T03:33:51.000ZEcoWaste Coalition Echoes FDA B.E.A.T. Reminders on Musical Toyshttps://www.pharmaradar360.com/article/glenmark-s-trastuzumab-rezetecan-phase-3-trial-for-ovarian-cancer-gets-dcgi-nod-67b0941aa5a4ccf0Pharma Surgeen2026-07-02T03:18:02.000ZGlenmark's Trastuzumab Rezetecan Phase 3 Trial for Ovarian Cancer Gets DCGI Nodhttps://www.pharmaradar360.com/article/gc-biopharma-announced-on-the-2nd-that-the-phase-3-clinical-trial-plan-ind-for-t-675ff4d614b23473Pharma Surgeen2026-07-02T01:49:56.000ZGC Biopharma announced on the 2nd that the phase 3 clinical trial plan (IND) for the chickenpox vacc..https://www.pharmaradar360.com/article/fda-alignment-to-advance-prostact-global-phase-3-trial-13ca93648e506c85Pharma Surgeen2026-07-02T01:36:50.000ZFDA Alignment to Advance ProstACT Global Phase 3 Trialhttps://www.pharmaradar360.com/article/anthropic-debuts-ai-driven-pharma-r-d-tool-claude-science-56a0a3b20209f8d7Pharma Surgeen2026-07-02T01:32:55.000ZAnthropic debuts AI-driven pharma R&D tool, Claude Sciencehttps://www.pharmaradar360.com/article/fda-alignment-to-advance-prostact-global-phase-3-trial-35ad7ca9e2debf8bPharma Surgeen2026-07-02T01:31:00.000ZFDA Alignment to Advance ProstACT Global Phase 3 Trialhttps://www.pharmaradar360.com/article/gni-group-completes-acquisition-of-ayumi-pharmaceutical-ee10e05a4cbf695fPharma Surgeen2026-07-02T01:07:00.000ZGNI Group Completes Acquisition of AYUMI Pharmaceuticalhttps://www.pharmaradar360.com/article/the-pill-that-is-being-used-against-women-the-fda-must-act-on-mifepristone-50e498e1d8205d04Pharma Surgeen2026-07-02T01:02:35.000ZThe pill that is being used against women: The FDA must act on mifepristone.https://www.pharmaradar360.com/article/insilico-keeps-partnership-sprint-apace-in-600m-biobucks-collab-with-takeda-156273267561fa77Pharma Surgeen2026-07-02T00:30:00.000ZInsilico keeps partnership sprint apace in $600M biobucks collab with Takedahttps://www.pharmaradar360.com/article/cytiva-executive-on-biotech-trends-challenges-and-innovation-1d92fbd027a5daf9Pharma Surgeen2026-07-02T00:09:18.000ZCytiva executive on biotech Trends, challenges, and innovationhttps://www.pharmaradar360.com/article/taiho-innovations-begins-operations-under-new-organizational-structure-establish-4dfbbb700f832621Pharma Surgeen2026-07-02T00:00:00.000ZTaiho Innovations Begins Operations Under New Organizational Structure Establishing an Early Clinical Development Function to Strengthen Its Co-Creation Platformhttps://www.pharmaradar360.com/article/otsuka-reports-positive-phase-3-visionary-two-year-egfr-results-demonstrating-vo-08039329e5a6a919Pharma Surgeen2026-07-02T00:00:00.000ZOtsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney Function in IgA Nephropathy (IgAN)https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-ee22597b75525531Pharma Surgeen2026-07-02T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-080a74eeccf75ab3Pharma Surgeen2026-07-02T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-54f42536cbf57580Pharma Surgeen2026-07-02T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-3ff39f3cff4365d0Pharma Surgeen2026-07-02T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-abdcba83e74d9804Pharma Surgeen2026-07-02T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-1de170e402a168d1Pharma Surgeen2026-07-02T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-39c7168a2aa65e81Pharma Surgeen2026-07-02T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-4236731d6191b012Pharma Surgeen2026-07-02T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-a3a430ef08c7beeePharma Surgeen2026-07-02T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-a0f3f83387bb958cPharma Surgeen2026-07-02T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-f50b47dbacce5e3cPharma Surgeen2026-07-02T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-30478ec9531fc7d7Pharma Surgeen2026-07-02T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-10924060f7aeb351Pharma Surgeen2026-07-02T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-2a9d2a05f6903aa4Pharma Surgeen2026-07-02T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/government-owned-invention-available-for-license-a-conserved-viral-peptide-for-u-fdfb6513dd337995Pharma Surgeen2026-07-02T00:00:00.000ZGovernment Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapyhttps://www.pharmaradar360.com/article/government-owned-invention-available-for-license-chimeric-vlp-vaccines-to-preven-5d6ec30cad77df0cPharma Surgeen2026-07-02T00:00:00.000ZGovernment Owned Invention Available for License: Chimeric VLP Vaccines To Prevent HTLV-1 Infectionhttps://www.pharmaradar360.com/article/agency-information-collection-request-60-day-public-comment-request-2b832cc42af17e1bPharma Surgeen2026-07-02T00:00:00.000ZAgency Information Collection Request. 60-Day Public Comment Requesthttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-cca1c23850ef3f5bPharma Surgeen2026-07-02T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/reducing-bureaucracy-and-burden-for-children-youth-and-family-programs-ab049ee995abaf55Pharma Surgeen2026-07-02T00:00:00.000ZReducing Bureaucracy and Burden for Children, Youth, and Family Programshttps://www.pharmaradar360.com/article/current-list-of-hhs-certified-laboratories-and-instrumented-initial-testing-faci-4e1a0af7e0073f40Pharma Surgeen2026-07-02T00:00:00.000ZCurrent List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencieshttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-chafee-strengthening-outco-395067dd2646fad6Pharma Surgeen2026-07-02T00:00:00.000ZSubmission for Office of Management and Budget Review; Chafee Strengthening Outcomes for Transition to Adulthood Project Overarching Generic (Extension)https://www.pharmaradar360.com/article/termination-of-declaration-authorizing-emergency-use-of-drug-and-biological-prod-7e0ae55228bc17c9Pharma Surgeen2026-07-02T00:00:00.000ZTermination of Declaration Authorizing Emergency Use of Drug and Biological Products During the COVID-19 Pandemichttps://www.pharmaradar360.com/article/termination-of-three-declarations-authorizing-emergency-use-of-medical-devices-d-a0a9a6d9b6d35868Pharma Surgeen2026-07-02T00:00:00.000ZTermination of Three Declarations Authorizing Emergency Use of Medical Devices During the COVID-19 Pandemichttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-office-of-refugee-resettle-b0a20fca6eaa8375Pharma Surgeen2026-07-02T00:00:00.000ZSubmission for Office of Management and Budget Review; Office of Refugee Resettlement Annual Survey of Refugeeshttps://www.pharmaradar360.com/article/united-therapeutics-corporation-acquires-thymmune-therapeutics-907f7bca31986c27Pharma Surgeen2026-07-02T00:00:00.000ZUnited Therapeutics Corporation Acquires Thymmune Therapeuticshttps://www.pharmaradar360.com/article/antioxidant-and-anti-apoptotic-activities-of-makiang-fruit-extract-in-arpe-19-ce-d05bfdaf801ea420Pharma Surgeen2026-07-02T00:00:00.000ZANTIOXIDANT AND ANTI-APOPTOTIC ACTIVITIES OF MAKIANG FRUIT EXTRACT IN ARPE-19 CELLS EXPOSED TO GLUCOSE-INDUCED CELLULAR DAMAGEhttps://www.pharmaradar360.com/article/holmium-lithotripsy-laser-assisted-endoscopic-retrieval-of-a-fish-bone-impacted-a59459682ba46fe1Pharma Surgeen2026-07-02T00:00:00.000ZHolmium lithotripsy laser-assisted endoscopic retrieval of a fish bone impacted in the esophagus: a rare extraction techniquehttps://www.pharmaradar360.com/article/opioid-free-anesthesia-current-evidence-clinical-applications-and-future-perspec-c2fd916d848d0d24Pharma Surgeen2026-07-02T00:00:00.000ZOpioid-Free Anesthesia: Current Evidence, Clinical Applications, and Future Perspectiveshttps://www.pharmaradar360.com/article/culture-conversion-and-drug-susceptibility-in-drug-resistant-pulmonary-tuberculo-760f453f0ef28ed1Pharma Surgeen2026-07-02T00:00:00.000ZCulture conversion and drug susceptibility in drug resistant pulmonary tuberculosis with type II diabetes mellitus on oral regimenshttps://www.pharmaradar360.com/article/staged-surgical-treatment-of-giant-renal-angiomyolipoma-with-preoperative-emboli-4bb8c63e574aeaa3Pharma Surgeen2026-07-02T00:00:00.000ZSTAGED SURGICAL TREATMENT OF GIANT RENAL ANGIOMYOLIPOMA WITH PREOPERATIVE EMBOLIZATION OF THE RENAL ARTERY: A CLINICAL CASEhttps://www.pharmaradar360.com/article/correction-yang-et-al-5-methylcytidine-rna-epitranscriptomics-in-women-s-health-d24be795c524397fPharma Surgeen2026-07-02T00:00:00.000ZCorrection: Yang et al. 5-Methylcytidine RNA Epitranscriptomics in Women’s Health and Disease: Mechanisms and Clinical Implications. Cells 2026, 15, 847https://www.pharmaradar360.com/article/implementation-of-sequencing-based-surveillance-for-drug-resistant-tuberculosis-5ff39f3ad424ec39Pharma Surgeen2026-07-02T00:00:00.000ZImplementation of sequencing-based surveillance for drug-resistant tuberculosis in Nigeriahttps://www.pharmaradar360.com/article/dynamic-phenotype-monitoring-to-prevent-genotype-phenotype-discrepancies-in-phar-5f187576059b858dPharma Surgeen2026-07-02T00:00:00.000ZDynamic phenotype monitoring to prevent genotype–phenotype discrepancies in pharmacogenetic-guided drug therapyhttps://www.pharmaradar360.com/article/severe-hepatotoxicity-associated-with-orlistat-clinical-presentation-risk-factor-cd086735ad04390dPharma Surgeen2026-07-02T00:00:00.000ZSevere hepatotoxicity associated with orlistat: clinical presentation, risk factors and outcomeshttps://www.pharmaradar360.com/article/prediction-of-histological-grading-in-ductal-carcinoma-in-situ-based-on-mammogra-1ebbbb6389f7986cPharma Surgeen2026-07-02T00:00:00.000ZPrediction of histological grading in ductal carcinoma in situ based on mammographic signs and clinical information using machine learning modelshttps://www.pharmaradar360.com/article/implications-of-autolysosome-astrocyte-associated-signature-in-the-pathogenesis-eb73fa37f04a3d1dPharma Surgeen2026-07-02T00:00:00.000ZImplications of autolysosome- astrocyte-associated signature in the pathogenesis of Alzheimer’s disease: evidence from artificial intelligence and multi-omics and clinical validationhttps://www.pharmaradar360.com/article/an-efficient-micropropagation-protocol-and-optimization-of-phytohormones-for-gla-28763d8feddb800ePharma Surgeen2026-07-02T00:00:00.000ZAn Efficient Micropropagation Protocol and Optimization of Phytohormones for Gladiolus Species for Commercial Cultivationhttps://www.pharmaradar360.com/article/in-vitro-mass-propagation-protocol-for-lobelia-chinensis-lour-optimization-of-gr-8007a4484587e2aaPharma Surgeen2026-07-02T00:00:00.000ZIn vitro Mass Propagation Protocol for Lobelia chinensis Lour.: Optimization of Growth Regulators and Acclimatizationhttps://www.pharmaradar360.com/article/furosemide-initiation-during-norepinephrine-infusion-and-proximal-hemodynamic-de-bd3720e4f59f50e9Pharma Surgeen2026-07-02T00:00:00.000ZFurosemide initiation during norepinephrine infusion and proximal hemodynamic destabilization: a target trial emulation in MIMIC-IV with external validation in eICU-CRDhttps://www.pharmaradar360.com/article/development-and-internal-validation-of-a-clinical-decision-support-nomogram-for-1b268b8263618e30Pharma Surgeen2026-07-02T00:00:00.000ZDevelopment and Internal Validation of a Clinical Decision Support Nomogram for Predicting Neonatal Intensive Care Unit Admission in Late-Onset Preeclampsiahttps://www.pharmaradar360.com/article/emerging-blood-based-diagnostic-strategies-for-tuberculosis-c3ac7e3719b95ce6Pharma Surgeen2026-07-02T00:00:00.000ZEmerging blood-based diagnostic strategies for tuberculosishttps://www.pharmaradar360.com/article/a-single-dose-of-azithromycin-and-inflammation-in-infants-a-cluster-randomized-p-0a103273567545abPharma Surgeen2026-07-02T00:00:00.000ZA Single Dose of Azithromycin and Inflammation in Infants – A Cluster Randomized Placebo-Controlled Trialhttps://www.pharmaradar360.com/article/primary-knee-osteoarthritis-do-the-clinical-and-functional-outcomes-of-intra-art-f5a6352b4d99c767Pharma Surgeen2026-07-02T00:00:00.000ZPrimary knee osteoarthritis: do the clinical and functional outcomes of intra-articular PRP correlate with MRI structural changes?https://www.pharmaradar360.com/article/correction-nanovaccines-with-ferroptosis-necroptosis-and-sting-activation-for-sy-0a43114f5a60c1e0Pharma Surgeen2026-07-02T00:00:00.000ZCorrection: Nanovaccines with ferroptosis, necroptosis and STING-activation for synergistic immunotherapyhttps://www.pharmaradar360.com/article/rare-emergence-of-delamanid-resistance-in-multidrug-rifampicin-resistant-tubercu-66ea86eb4dd80583Pharma Surgeen2026-07-02T00:00:00.000ZRare emergence of delamanid resistance in multidrug-/rifampicin-resistant tuberculosis patients receiving delamanid-containing regimens: a prospective multicentric study in Chinahttps://www.pharmaradar360.com/article/technical-and-clinical-feasibility-of-single-use-gastroscopy-with-real-time-ai-b-23d841fbdab544d2Pharma Surgeen2026-07-02T00:00:00.000ZTechnical and clinical feasibility of single-use gastroscopy with real-time AI-based quality monitoring and single-use colonoscopy: a prospective two-center studyhttps://www.pharmaradar360.com/article/molecular-prevalence-and-clinical-profiles-of-canine-babesiosis-in-northern-indi-b68158f658b02609Pharma Surgeen2026-07-02T00:00:00.000ZMolecular prevalence and clinical profiles of canine babesiosis in northern Indiahttps://www.pharmaradar360.com/article/artificial-intelligence-assisted-telemedicine-clinical-decision-support-for-anes-ee311f6769247f67Pharma Surgeen2026-07-02T00:00:00.000ZArtificial intelligence assisted telemedicine, clinical decision support for anesthesia and critical care in intensive care units: a scoping reviewhttps://www.pharmaradar360.com/article/invited-commentary-using-large-clinical-databases-1af5bbeeed62795cPharma Surgeen2026-07-02T00:00:00.000ZInvited Commentary: Using Large Clinical Databaseshttps://www.pharmaradar360.com/article/t-bet-expression-in-b-cell-subsets-association-with-t-peripheral-helper-cells-an-9598c40465989e40Pharma Surgeen2026-07-02T00:00:00.000ZT-bet expression in B cell subsets: Association with T peripheral helper cells and clinical activity in systemic lupus erythematosushttps://www.pharmaradar360.com/article/safety-and-feasibility-of-moderate-intensity-home-based-guided-exercise-in-aorti-f5a8bb0281b56de7Pharma Surgeen2026-07-02T00:00:00.000ZSafety and Feasibility of Moderate-Intensity Home-Based Guided Exercise in Aortic Dissection Survivors in the United States: A Multicenter Randomized Controlled Trialhttps://www.pharmaradar360.com/article/abstract-p87-drug-induced-hyperactivation-of-the-oncogene-kras-induces-ferroptos-71281cf0161ff8ccPharma Surgeen2026-07-02T00:00:00.000ZAbstract P87: Drug-induced Hyperactivation of the oncogene KRAS induces ferroptosis in G12-mutant KRAS Pancreatic Ductal Adenocarcinoma (PDAC)https://www.pharmaradar360.com/article/abstract-p69-covalent-inhibition-of-clic1-a-novel-strategy-for-anti-cancer-drug-4f6a132ca5e241c3Pharma Surgeen2026-07-02T00:00:00.000ZAbstract P69: Covalent Inhibition of CLIC1: A Novel Strategy for Anti-Cancer Drug Discoveryhttps://www.pharmaradar360.com/article/data-from-preclinical-to-clinical-translation-of-pharmacokinetic-pharmacodynamic-3e8b513f92732e4ePharma Surgeen2026-07-02T00:00:00.000ZData from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitorshttps://www.pharmaradar360.com/article/supplementary-figure-10-from-preclinical-to-clinical-translation-of-pharmacokine-5bd6759e0347cbd3Pharma Surgeen2026-07-02T00:00:00.000ZSupplementary Figure 10 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitorshttps://www.pharmaradar360.com/article/supplementary-figure-4-from-preclinical-to-clinical-translation-of-pharmacokinet-423a20508f0e8cc8Pharma Surgeen2026-07-02T00:00:00.000ZSupplementary Figure 4 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitorshttps://www.pharmaradar360.com/article/supplementary-figure-6-from-preclinical-to-clinical-translation-of-pharmacokinet-57ba3a7465cbeb37Pharma Surgeen2026-07-02T00:00:00.000ZSupplementary Figure 6 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitorshttps://www.pharmaradar360.com/article/supplementary-fig-1-from-identification-and-preclinical-evaluation-of-a-novel-gd-6015f40ff0fceacdPharma Surgeen2026-07-02T00:00:00.000ZSupplementary Fig.1 from Identification and Preclinical Evaluation of a Novel GD2 Antibody–Drug Conjugate for Solid Tumors in Children and Adultshttps://www.pharmaradar360.com/article/supplementary-fig-6-from-identification-and-preclinical-evaluation-of-a-novel-gd-fa62d1cb061d87d2Pharma Surgeen2026-07-02T00:00:00.000ZSupplementary Fig.6 from Identification and Preclinical Evaluation of a Novel GD2 Antibody–Drug Conjugate for Solid Tumors in Children and Adultshttps://www.pharmaradar360.com/article/a-service-evaluation-of-a-specialist-multi-disciplinary-weight-management-servic-b874981b1f88941aPharma Surgeen2026-07-02T00:00:00.000ZA Service Evaluation of a Specialist Multi‐Disciplinary Weight Management Service Based in Primary Care Including Long‐Term Follow‐Up Datahttps://www.pharmaradar360.com/article/cardiopulmonary-exercise-testing-in-australia-and-new-zealand-a-survey-of-curren-afa33545766f7d71Pharma Surgeen2026-07-02T00:00:00.000ZCardiopulmonary Exercise Testing in Australia and New Zealand: A SURVEY OF CURRENT CLINICAL PRACTICEhttps://www.pharmaradar360.com/article/bacillus-calmette-guerin-bcg-immunotherapy-reprograms-cns-immunity-and-alters-al-78c73a112c9d5eb4Pharma Surgeen2026-07-02T00:00:00.000ZBacillus Calmette–Guérin (BCG) immunotherapy reprograms CNS immunity and alters Alzheimer’s biomarkers: results from two open-label clinical trialshttps://www.pharmaradar360.com/article/cambridge-studies-in-law-and-society-cbdecca2319032a2Pharma Surgeen2026-07-02T00:00:00.000ZCambridge Studies in Law and Societyhttps://www.pharmaradar360.com/article/bibliography-0e3e266cd76477a4Pharma Surgeen2026-07-02T00:00:00.000ZBibliographyhttps://www.pharmaradar360.com/article/comparative-risk-of-ventricular-arrhythmia-and-sudden-cardiac-death-among-acetyl-53afbaf1247b1397Pharma Surgeen2026-07-02T00:00:00.000ZComparative risk of ventricular arrhythmia and sudden cardiac death among acetylcholinesterase inhibitors in dementia: A population‐based cohort studyhttps://www.pharmaradar360.com/article/world-pharmaceutical-grade-amino-acid-global-market-analysis-forecast-size-trend-2f3e4671f32ef131Pharma Surgeen2026-07-01T23:56:20.000ZWorld Pharmaceutical Grade Amino Acid Global - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/aob-pharma-taps-biorasi-to-execute-phase-2b-acne-trial-company-maintains-phase-3-4ef23e8c678de3e7Pharma Surgeen2026-07-01T22:27:22.000ZAOB Pharma Taps Biorasi to Execute Phase 2b Acne Trial; Company Maintains Phase 3 AD Trial Timelinehttps://www.pharmaradar360.com/article/draft-for-comments-guidelines-on-the-classification-of-deficiencies-observed-dur-09cb62c77aab8305Pharma Surgeen2026-07-01T21:25:02.000ZDraft for Comments || Guidelines on the Classification of Deficiencies Observed During Inspection of Drug Distributors, Drugstores, Hospital Pharmacies and Retail Outlet for Non-Prescription Drugs (RONPD)https://www.pharmaradar360.com/article/kcmc-drives-korea-to-build-cmc-muscle-cut-china-reliance-win-drug-approvals-chos-49f202d6d6d33fadPharma Surgeen2026-07-01T21:01:00.000ZKCMC drives Korea to build CMC muscle, cut China reliance, win drug approvals - CHOSUNBIZhttps://www.pharmaradar360.com/article/rentschler-biopharma-hires-swiss-biotech-executive-as-next-ceo-cd60b412a92f5be1Pharma Surgeen2026-07-01T20:56:24.000ZRentschler BioPharma hires Swiss biotech executive as next CEOhttps://www.pharmaradar360.com/article/wall-street-thinks-this-high-flying-biotech-stock-can-soar-another-57-b8fe570097cabfbbPharma Surgeen2026-07-01T20:45:00.000ZWall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%https://www.pharmaradar360.com/article/can-ozempic-cause-joint-and-muscle-pain-f9f7e2e1cf0fa136Pharma Surgeen2026-07-01T20:29:01.000ZCan Ozempic Cause Joint and Muscle Pain?https://www.pharmaradar360.com/article/lsd-therapy-biotech-definium-fends-off-trade-secret-lawsuit-7a0a5d3dced52211Pharma Surgeen2026-07-01T20:15:34.000ZLSD therapy biotech Definium fends off trade-secret lawsuithttps://www.pharmaradar360.com/article/the-medicare-glp-1-bridge-pharmexec-0de7b67fcdffacd9Pharma Surgeen2026-07-01T19:52:53.000ZThe Medicare GLP-1 Bridge | PharmExechttps://www.pharmaradar360.com/article/what-do-moonlake-s-latest-week-40-hs-results-really-mean-for-investors-9f702ce2a4a5c8ffPharma Surgeen2026-07-01T19:15:53.000ZWhat Do MoonLake's Latest Week 40 HS Results Really Mean for Investorshttps://www.pharmaradar360.com/article/biotech-s-resurgence-a-video-recap-of-bio-2026-5fbc3c3c6eb6df24Pharma Surgeen2026-07-01T18:44:03.000ZBiotech's Resurgence: A Video Recap of BIO 2026https://www.pharmaradar360.com/article/nueva-convocatoria-de-la-revista-cientifica-anmat-98174685cba8e209Pharma Surgeen2026-07-01T16:46:15.000ZNueva convocatoria de la Revista Científica ANMAThttps://www.pharmaradar360.com/article/june-s-top-etfs-biotech-china-semiconductors-surge-54047aa893f55ba8Pharma Surgeen2026-07-01T16:35:18.000ZJune's Top ETFs: Biotech & China Semiconductors Surgehttps://www.pharmaradar360.com/article/14-new-weight-loss-drugs-8f97f67645d6c678Pharma Surgeen2026-07-01T16:30:21.000Z14 New Weight Loss Drugshttps://www.pharmaradar360.com/article/the-acta-just-got-an-upgrade-d847f71c5d67e575Pharma Surgeen2026-07-01T16:18:24.000ZThe ACTA Just Got an Upgradehttps://www.pharmaradar360.com/article/medicare-will-spend-more-than-13-billion-on-the-medicare-advantage-quality-bonus-2a82a6a0bff86a8dPharma Surgeen2026-07-01T16:15:00.000ZMedicare Will Spend More Than $13 Billion on the Medicare Advantage Quality Bonus Program in 2026https://www.pharmaradar360.com/article/decoding-medicare-advantage-coding-intensity-74892946070d5963Pharma Surgeen2026-07-01T16:15:00.000ZDecoding Medicare Advantage Coding Intensityhttps://www.pharmaradar360.com/article/carolina-s-school-of-data-and-information-sciences-launches-3bcc4095492be6abPharma Surgeen2026-07-01T16:10:40.000ZCarolina’s School of Data and Information Sciences launcheshttps://www.pharmaradar360.com/article/collaboration-is-key-for-carolina-s-newest-school-d3925202e1effa31Pharma Surgeen2026-07-01T16:09:09.000ZCollaboration is key for Carolina’s newest schoolhttps://www.pharmaradar360.com/article/10-million-gift-launches-statewide-effort-to-expand-access-to-care-in-rural-alab-eff6204cc1984890Pharma Surgeen2026-07-01T16:07:53.000Z$10 million gift launches statewide effort to expand access to care in rural Alabamahttps://www.pharmaradar360.com/article/skin-cancer-risk-in-congenital-ichthyoses-how-all-of-us-data-supports-real-world-e7372772e9715505Pharma Surgeen2026-07-01T16:07:32.000ZSkin Cancer Risk in Congenital Ichthyoses: How All of Us Data Supports Real-World Rare Disease Researchhttps://www.pharmaradar360.com/article/oxford-researchers-become-embo-members-76884d7309bb0d70Pharma Surgeen2026-07-01T16:02:00.000ZOxford researchers become EMBO membershttps://www.pharmaradar360.com/article/fda-scientists-warn-against-expanded-peptide-access-as-kennedy-reshapes-advisory-b66242723092caa6Pharma Surgeen2026-07-01T16:01:37.000ZFDA Scientists Warn Against Expanded Peptide Access As Kennedy Reshapes Advisory Panelhttps://www.pharmaradar360.com/article/jacob-smith-defies-early-prognosis-following-life-threatening-accident-664224178bee1dc0Pharma Surgeen2026-07-01T15:59:52.000ZJacob Smith defies early prognosis following life-threatening accidenthttps://www.pharmaradar360.com/article/medicare-s-glp-1-bridge-and-what-s-next-for-biotech-lly-nyse-4470e3b9b275cd47Pharma Surgeen2026-07-01T15:55:01.000ZMedicare's GLP-1 Bridge and what's next for biotech (LLY:NYSE)https://www.pharmaradar360.com/article/safe-use-of-electronic-devices-on-planes-3e53bd1d35dde82cPharma Surgeen2026-07-01T15:52:00.000ZSafe Use of Electronic Devices on Planeshttps://www.pharmaradar360.com/article/reliably-detecting-and-clearly-explaining-deepfake-images-dab264151fdd5c86Pharma Surgeen2026-07-01T15:52:00.000ZReliably Detecting and Clearly Explaining Deepfake Imageshttps://www.pharmaradar360.com/article/adressing-the-shortage-of-skilled-workers-with-lars-03b8c55e3a4c38adPharma Surgeen2026-07-01T15:52:00.000ZAdressing the Shortage of Skilled Workers With LARShttps://www.pharmaradar360.com/article/what-to-know-about-male-infertility-from-a-uab-urologist-9cc2608f34495905Pharma Surgeen2026-07-01T15:51:18.000ZWhat to know about male infertility from a UAB urologisthttps://www.pharmaradar360.com/article/teva-launches-hydrogen-truck-for-pharmaceutical-logistics-29d0fb0521d3abfdPharma Surgeen2026-07-01T15:50:00.000ZTeva Launches Hydrogen Truck for Pharmaceutical Logisticshttps://www.pharmaradar360.com/article/fda-recalls-and-warnings-foreign-substance-found-in-millions-of-steroid-eye-drop-3d4bb5dbe80252bfPharma Surgeen2026-07-01T15:38:09.000ZFDA Recalls and Warnings: Foreign Substance Found in Millions of Steroid Eye Drops, Seizure Drug Mix-Up & Morehttps://www.pharmaradar360.com/article/extreme-heat-is-rising-and-so-is-the-risk-to-your-heart-72e193ae4bf3db81Pharma Surgeen2026-07-01T15:30:00.000ZExtreme heat is rising — and so is the risk to your hearthttps://www.pharmaradar360.com/article/quantumcell-commits-2-2bn-on-alzecure-s-alzheimer-s-platform-344766e0011da79ePharma Surgeen2026-07-01T15:27:52.000ZQuantumCell commits $2.2bn on AlzeCure’s Alzheimer’s platformhttps://www.pharmaradar360.com/article/how-amendment-intelligence-helps-reduce-avoidable-protocol-revisions-c9a94cbc3f8e1244Pharma Surgeen2026-07-01T15:27:20.000ZHow Amendment Intelligence Helps Reduce Avoidable Protocol Revisionshttps://www.pharmaradar360.com/article/guidance-mhra-innovation-office-guidance-and-support-e3617b6abf32ab4ePharma Surgeen2026-07-01T15:26:45.000ZGuidance: MHRA Innovation Office: guidance and supporthttps://www.pharmaradar360.com/article/pfas-free-coatings-for-mdi-canisters-what-to-look-for-92f6f285972821e8Pharma Surgeen2026-07-01T15:22:53.000ZPFAS-free coatings for MDI canisters: What to look forhttps://www.pharmaradar360.com/article/bristol-myers-squibb-hires-lobbyist-on-drug-pricing-6fa0b056f7881fbePharma Surgeen2026-07-01T15:22:20.000ZBristol-Myers Squibb Hires Lobbyist on Drug Pricinghttps://www.pharmaradar360.com/article/postpartum-reintegration-an-uncomfortable-silence-pharmacy-can-no-longer-afford-8058a5c7f3fc1ebePharma Surgeen2026-07-01T15:15:54.000ZPostpartum reintegration: an uncomfortable silence pharmacy can no longer affordhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-welgene-biotech-co-ltd-tpex-6661-ba5b87640fd8ef80Pharma Surgeen2026-07-01T15:12:37.000ZPrice to earnings forward of Welgene Biotech Co., Ltd. – TPEX:6661https://www.pharmaradar360.com/article/devolved-governments-seen-to-favour-some-regions-e49247e1178d3a46Pharma Surgeen2026-07-01T14:59:25.000ZDevolved governments seen to favour some regionshttps://www.pharmaradar360.com/article/biophorum-unites-20-organizations-to-modernize-small-molecule-production-e2e4918eaded20e5Pharma Surgeen2026-07-01T14:53:53.000ZBioPhorum Unites 20 Organizations to Modernize Small Molecule Productionhttps://www.pharmaradar360.com/article/collegium-pharmaceutical-stock-gains-12-in-three-months-here-s-why-bf1cf301b555f476Pharma Surgeen2026-07-01T14:41:00.000ZCollegium Pharmaceutical Stock Gains 12% in Three Months: Here's Whyhttps://www.pharmaradar360.com/article/programa-capes-augm-para-proyectos-conjuntos-de-investigacion-2026-y-2027-45bc240aa4549643Pharma Surgeen2026-07-01T14:36:13.000ZPrograma CAPES/AUGM para proyectos conjuntos de investigación 2026 Y 2027https://www.pharmaradar360.com/article/biotechs-in-better-position-to-avoid-workforce-reductions-as-layoffs-continue-to-14d96801d466744dPharma Surgeen2026-07-01T14:30:00.000ZBiotechs ‘in better position to avoid workforce reductions’ as layoffs continue to ease in Q2’26https://www.pharmaradar360.com/article/alzecure-pharma-enters-2-2-billion-licensing-and-collaboration-agreement-with-qu-451e97d9cb3f7782Pharma Surgeen2026-07-01T14:29:27.000ZAlzeCure Pharma Enters $2.2 Billion Licensing and Collaboration Agreement with QuantumCell ApShttps://www.pharmaradar360.com/article/ipsen-to-buy-swiss-biotech-memo-therapeutics-in-potential-800m-deal-76355d597a466e75Pharma Surgeen2026-07-01T14:27:15.000ZIpsen to buy Swiss biotech Memo Therapeutics in potential $800M dealhttps://www.pharmaradar360.com/article/what-s-really-driving-the-direct-to-patient-boom-929b73c93e4170c1Pharma Surgeen2026-07-01T14:25:20.000ZWhat's Really Driving the Direct-to-Patient Boom?https://www.pharmaradar360.com/article/us-judge-pauses-louisiana-s-challenge-to-fda-abortion-drug-rule-83c1eec8eab99369Pharma Surgeen2026-07-01T14:20:12.000ZUS judge pauses Louisiana’s challenge to FDA abortion drug rulehttps://www.pharmaradar360.com/article/medicines-packaging-labelling-and-patient-information-leaflets-c74904453a186685Pharma Surgeen2026-07-01T14:18:01.000ZMedicines: packaging, labelling and patient information leafletshttps://www.pharmaradar360.com/article/guidance-warning-statements-for-labels-and-leaflets-of-certain-medicines-647ee78898397083Pharma Surgeen2026-07-01T14:17:56.000ZGuidance: Warning statements for labels and leaflets of certain medicineshttps://www.pharmaradar360.com/article/guidance-best-practice-guidance-on-patient-information-leaflets-81f4119e573b76e0Pharma Surgeen2026-07-01T14:17:53.000ZGuidance: Best practice guidance on patient information leafletshttps://www.pharmaradar360.com/article/vamreg-disponible-a-partir-du-1-juillet-2026-debut-de-l-enregistrement-obligatoi-836b05034938ac9aPharma Surgeen2026-07-01T14:12:52.000ZVAMREG disponible à partir du 1 juillet 2026 : début de l’enregistrement obligatoire des antibiotiques à usage vétérinairehttps://www.pharmaradar360.com/article/one-step-closer-fda-removes-prohibitions-on-drug-testing-devices-build-america-2-f5cb765c9c5d9d64Pharma Surgeen2026-07-01T14:02:58.000ZOne step closer: FDA removes prohibitions on drug testing devices; BUILD America 250 pushes hair testinghttps://www.pharmaradar360.com/article/collegium-pharmaceutical-stock-gains-12-in-three-months-here-s-why-a102e20e329cf347Pharma Surgeen2026-07-01T14:02:32.000ZCollegium Pharmaceutical Stock Gains 12% in Three Months: Here's Whyhttps://www.pharmaradar360.com/article/american-heart-association-announces-volunteer-leaders-for-2026-27-44f1f7f168c50457Pharma Surgeen2026-07-01T14:00:00.000ZAmerican Heart Association announces volunteer leaders for 2026-27https://www.pharmaradar360.com/article/compras-y-contrataciones-bd7e1911203b8ea5Pharma Surgeen2026-07-01T13:57:09.000ZCompras y Contratacioneshttps://www.pharmaradar360.com/article/centenario-de-spegazzini-visitas-guiadas-estreno-audiovisual-y-feria-fungi-8870fccbb0acedb9Pharma Surgeen2026-07-01T13:49:20.000ZCentenario de Spegazzini: visitas guiadas, estreno audiovisual y Feria Fungihttps://www.pharmaradar360.com/article/anthropic-launches-ai-initiative-for-life-sciences-7c8c8d93cbd744aaPharma Surgeen2026-07-01T13:48:45.000ZAnthropic launches AI initiative for life scienceshttps://www.pharmaradar360.com/article/protecting-temperature-integrity-in-extreme-heat-how-csafe-s-cold-chain-portfoli-96766acce2efa146Pharma Surgeen2026-07-01T13:40:54.000ZProtecting Temperature Integrity in Extreme Heat: How CSafe’s Cold Chain Portfolio Addresses the Riskhttps://www.pharmaradar360.com/article/more-signs-that-glp-1s-may-help-with-peripheral-artery-disease-92ac28f69f84b95fPharma Surgeen2026-07-01T13:40:39.000ZMore signs that GLP-1s may help with peripheral artery diseasehttps://www.pharmaradar360.com/article/eu-gefordertes-forschungsprojekt-zu-bauchspeicheldrusenkrebs-medizinische-fakult-7ddab42f47b10f3ePharma Surgeen2026-07-01T13:38:33.000ZEU-gefördertes Forschungsprojekt zu Bauchspeicheldrüsenkrebs: Medizinische Fakultät Heidelberg nimmt Schlüsselrolle einhttps://www.pharmaradar360.com/article/la-nouvelle-application-web-biovigilance-est-disponible-5e93ed530622a4a8Pharma Surgeen2026-07-01T13:29:58.000ZLa nouvelle application web BioVigilance est disponible !https://www.pharmaradar360.com/article/angitia-ends-phase-3-in-disc-disease-abivax-targets-800m-on-colitis-data-f4b385d383ebefcdPharma Surgeen2026-07-01T13:29:00.000ZAngitia ends Phase 3 in disc disease; Abivax targets $800M on colitis datahttps://www.pharmaradar360.com/article/surge-in-rmat-designations-awarded-by-the-fda-ada778bfba0a1922Pharma Surgeen2026-07-01T13:08:11.000ZSurge in RMAT designations awarded by the FDAhttps://www.pharmaradar360.com/article/cordis-project-cliniccards-voxel-based-ai-for-3d-dental-diagnostics-336b8f85884a0dd4Pharma Surgeen2026-07-01T13:05:22.000ZCORDIS project: CLINICCARDS: Voxel-Based AI for 3D Dental Diagnosticshttps://www.pharmaradar360.com/article/cordis-project-precision-biochemistry-for-women-s-health-the-first-dual-self-tes-008be3dc6fa08dd1Pharma Surgeen2026-07-01T13:05:00.000ZCORDIS project: Precision biochemistry for women’s health - the first dual self-test for accurate at-home detection of bacterial vaginosis and vulvovaginal candidiasishttps://www.pharmaradar360.com/article/cordis-project-exploring-extended-field-of-view-pet-for-precision-medicine-9baa92634743426dPharma Surgeen2026-07-01T13:04:49.000ZCORDIS project: Exploring Extended Field-of-view PET for precision medicinehttps://www.pharmaradar360.com/article/cordis-project-a-multi-stage-malaria-vaccine-for-control-and-elimination-127ba1247092b81ePharma Surgeen2026-07-01T13:04:29.000ZCORDIS project: A Multi-stage Malaria Vaccine for Control and Eliminationhttps://www.pharmaradar360.com/article/prague-the-up-and-coming-biotech-hub-in-central-europe-c48ef67c994c5ddfPharma Surgeen2026-07-01T13:04:25.000ZPrague: The up-and-coming biotech hub in Central Europehttps://www.pharmaradar360.com/article/cordis-project-personalized-disease-prediction-and-prevention-in-chronic-inflamm-dc682383b7c99e54Pharma Surgeen2026-07-01T13:04:22.000ZCORDIS project: Personalized disease prediction and prevention in chronic inflammatory disordershttps://www.pharmaradar360.com/article/cholesterol-and-heart-medications-were-recalled-early-this-year-here-is-what-sta-7b776d5ef0af224ePharma Surgeen2026-07-01T13:01:11.000ZCholesterol and Heart Medications Were Recalled Early This Year — Here Is What Statin Users Should Checkhttps://www.pharmaradar360.com/article/why-a-just-transition-to-a-more-sustainable-future-needs-better-law-e12a7337bbe9b8faPharma Surgeen2026-07-01T13:00:00.000ZWhy a just transition to a more sustainable future needs better lawhttps://www.pharmaradar360.com/article/33-jornadas-de-jovenes-investigadores-en-brasil-augm-508af5dec6ef963fPharma Surgeen2026-07-01T12:55:12.000Z33° Jornadas de Jóvenes Investigadores en Brasil (AUGM)https://www.pharmaradar360.com/article/covid-19-vaccine-boosters-may-help-protect-against-future-animal-coronaviruses-af72d116c77c6b0ePharma Surgeen2026-07-01T12:53:45.000ZCOVID-19 vaccine boosters may help protect against future animal coronaviruseshttps://www.pharmaradar360.com/article/biotech-startup-turns-to-space-to-manufacture-artificial-retinas-for-treating-bl-38ccb81ed82e5abePharma Surgeen2026-07-01T12:50:00.000ZBiotech Startup Turns to Space to Manufacture Artificial Retinas for Treating Blindnesshttps://www.pharmaradar360.com/article/running-for-science-and-better-health-kemri-s-inaugural-community-cross-country-38d374172c96e6d5Pharma Surgeen2026-07-01T12:46:40.000ZRunning for Science and Better Health: KEMRI’s Inaugural Community Cross Country Run Sets the Pace for Health Researchhttps://www.pharmaradar360.com/article/kemri-joins-initiative-to-strengthen-africa-s-next-generation-of-malaria-researc-3a73ce2a959ae06ePharma Surgeen2026-07-01T12:44:49.000ZKEMRI Joins Initiative to Strengthen Africa’s Next Generation of Malaria Research Leadershttps://www.pharmaradar360.com/article/amgen-or-biogen-which-biotech-stock-appears-better-poised-a63505cec977bdc9Pharma Surgeen2026-07-01T12:41:47.000ZAmgen or Biogen: Which Biotech Stock Appears Better Poised?https://www.pharmaradar360.com/article/tanti-auguri-pierina-100-anni-4e33f2841a32b8f4Pharma Surgeen2026-07-01T12:35:35.000ZTanti auguri Pierina, 100 anni!https://www.pharmaradar360.com/article/uk-must-do-more-on-access-to-rare-disease-medicines-says-abpi-96670e9e722f7dfbPharma Surgeen2026-07-01T12:34:15.000ZUK must do more on access to rare disease medicines, says ABPIhttps://www.pharmaradar360.com/article/partnerships-build-trust-between-industry-and-healthcare-professionals-aa249be27804f901Pharma Surgeen2026-07-01T12:34:15.000ZPartnerships build trust between industry and healthcare professionalshttps://www.pharmaradar360.com/article/public-attitudes-on-the-pharmaceutical-industry-will-increasing-familiarity-buil-b05c2353e306f48bPharma Surgeen2026-07-01T12:34:14.000ZPublic attitudes on the pharmaceutical industry: will increasing familiarity build confidence?https://www.pharmaradar360.com/article/international-comparisons-in-medicines-spending-and-the-link-to-competitiveness-81d855d6faa52709Pharma Surgeen2026-07-01T12:34:14.000ZInternational comparisons in medicines spending and the link to competitivenesshttps://www.pharmaradar360.com/article/trust-transparency-and-purpose-managing-reputation-in-a-challenging-environment-4ec78e119f5bf413Pharma Surgeen2026-07-01T12:34:14.000ZTrust, transparency and purpose – managing reputation in a challenging environmenthttps://www.pharmaradar360.com/article/familiarity-and-trust-why-it-matters-to-industry-reputation-and-what-we-can-we-d-f523a215ca3a2a2aPharma Surgeen2026-07-01T12:34:13.000ZFamiliarity and trust: Why it matters to industry reputation and what we can we do about ithttps://www.pharmaradar360.com/article/eli-lilly-s-40m-bet-on-ai-designed-injectable-antibody-sparks-36-rally-37ff8036a53d677fPharma Surgeen2026-07-01T12:31:50.000ZEli Lilly’s $40M Bet on AI-Designed Injectable Antibody Sparks 36% Rallyhttps://www.pharmaradar360.com/article/duloxetine-generic-cymbalta-recalled-over-potential-cancer-causing-compound-here-ef9c9c9277de982bPharma Surgeen2026-07-01T12:30:05.000ZDuloxetine (Generic Cymbalta) Recalled Over Potential Cancer-Causing Compound: Here Are the Lot Numbers to Checkhttps://www.pharmaradar360.com/article/duloxetine-generic-cymbalta-recalled-over-potential-99763fb57843af2ePharma Surgeen2026-07-01T12:30:05.000ZDuloxetine (Generic Cymbalta) Recalled Over Potential…https://www.pharmaradar360.com/article/amneal-s-new-u-s-sterile-manufacturing-facility-selected-for-fda-precheck-pilot-34e0f6ac120d3086Pharma Surgeen2026-07-01T12:30:00.000ZAmneal’s New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Programhttps://www.pharmaradar360.com/article/improved-early-warning-systems-needed-to-reduce-medicines-supply-risks-says-abpi-0ff9e3aab10402e7Pharma Surgeen2026-07-01T12:29:48.000ZImproved early warning systems needed to reduce medicines supply risks, says ABPIhttps://www.pharmaradar360.com/article/unlocking-nhs-data-to-increase-recruitment-into-clinical-trials-will-give-the-uk-92534653bc5d2139Pharma Surgeen2026-07-01T12:29:47.000ZUnlocking NHS data to increase recruitment into clinical trials will give the UK a competitive edge, says ABPIhttps://www.pharmaradar360.com/article/life-sciences-sector-policy-delivery-68429ca6fdb6c8c7Pharma Surgeen2026-07-01T12:29:47.000ZLife Sciences Sector Policy Deliveryhttps://www.pharmaradar360.com/article/abpi-response-to-publication-of-england-s-rare-diseases-action-plan-2026-1893ae34a1dad84dPharma Surgeen2026-07-01T12:29:47.000ZABPI response to publication of England's Rare Diseases Action Plan 2026https://www.pharmaradar360.com/article/abpi-response-to-national-cancer-plan-f590be0aea10d346Pharma Surgeen2026-07-01T12:29:43.000ZABPI response to National Cancer Planhttps://www.pharmaradar360.com/article/abpi-comment-on-measles-outbreak-and-childhood-vaccination-0554ac809ee63790Pharma Surgeen2026-07-01T12:29:43.000ZABPI comment on measles outbreak and childhood vaccinationhttps://www.pharmaradar360.com/article/the-uk-should-seek-to-be-a-european-leader-for-rare-disease-medicine-says-new-re-caf0bfd881490b33Pharma Surgeen2026-07-01T12:29:43.000ZThe UK should seek to be a European leader for rare disease medicine, says new reporthttps://www.pharmaradar360.com/article/abpi-celebrates-a-month-of-major-investment-commitments-into-uk-life-sciences-2aa5a02f8c885674Pharma Surgeen2026-07-01T12:29:43.000ZABPI celebrates a month of major investment commitments into UK life scienceshttps://www.pharmaradar360.com/article/uk-tumbles-down-global-rankings-for-pharma-investment-and-research-0343d3b8ae14b440Pharma Surgeen2026-07-01T12:29:42.000ZUK tumbles down global rankings for pharma investment and researchhttps://www.pharmaradar360.com/article/the-uk-risks-undervaluing-life-sciences-manufacturing-investment-56a23fbf03e7ed1cPharma Surgeen2026-07-01T12:29:42.000ZThe UK risks undervaluing life sciences manufacturing investmenthttps://www.pharmaradar360.com/article/companies-granted-extension-to-vpag-2026-decision-deadline-97964c098c6bf889Pharma Surgeen2026-07-01T12:29:42.000ZCompanies granted extension to VPAG 2026 decision deadlinehttps://www.pharmaradar360.com/article/abpi-launches-manifesto-to-make-scotland-a-leader-in-r-d-and-cutting-edge-medici-e5abfa135e10b476Pharma Surgeen2026-07-01T12:29:41.000ZABPI launches manifesto to make Scotland a leader in R&D and cutting-edge medicineshttps://www.pharmaradar360.com/article/companies-granted-further-extension-to-vpag-2026-decision-deadline-267fe49733755de7Pharma Surgeen2026-07-01T12:29:41.000ZCompanies granted further extension to VPAG 2026 decision deadlinehttps://www.pharmaradar360.com/article/scotland-s-life-sciences-strategy-is-a-welcome-vision-that-must-be-matched-with-6f1fb59c5fd6428cPharma Surgeen2026-07-01T12:29:41.000ZScotland's life sciences strategy is a welcome vision that must be matched with delivery, says ABPIhttps://www.pharmaradar360.com/article/abivax-s-ulcerative-colitis-drug-clears-safety-hurdle-stock-surges-nearly-40-to-658db1c03348c55dPharma Surgeen2026-07-01T12:25:00.000ZAbivax's Ulcerative Colitis Drug Clears Safety Hurdle, Stock Surges Nearly 40% to Recover Losseshttps://www.pharmaradar360.com/article/new-external-member-of-university-council-8ce90bb6e3a51834Pharma Surgeen2026-07-01T12:22:16.000ZNew External Member of University Councilhttps://www.pharmaradar360.com/article/reliability-determines-success-in-the-biotech-industry-593cf57750fe86cePharma Surgeen2026-07-01T12:16:17.000ZReliability Determines Success in the Biotech Industryhttps://www.pharmaradar360.com/article/quantum-a-risk-worth-taking-1d34c1f470a6840ePharma Surgeen2026-07-01T12:07:24.000ZQuantum: A risk worth takinghttps://www.pharmaradar360.com/article/ipsen-gets-the-memo-penning-700m-deal-to-buy-rare-disease-biotech-for-clinical-s-069357c690ca23aaPharma Surgeen2026-07-01T12:05:39.000ZIpsen gets the Memo, penning €700M deal to buy rare disease biotech for clinical-stage assethttps://www.pharmaradar360.com/article/sarepta-secures-early-2027-fda-decision-for-duchenne-drugs-pushing-past-confirma-0928c2e825bda76dPharma Surgeen2026-07-01T12:01:50.000ZSarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory failhttps://www.pharmaradar360.com/article/tavneos-recall-pressure-mounts-as-eu-joins-fda-seeking-market-removal-9cd89ac8e341a711Pharma Surgeen2026-07-01T12:00:00.000ZTavneos Recall Pressure Mounts, As EU Joins FDA Seeking Market Removalhttps://www.pharmaradar360.com/article/escuela-de-invierno-2026-a-50-anos-del-golpe-civico-militar-106dcd4c1dcdbe79Pharma Surgeen2026-07-01T11:59:47.000ZEscuela de Invierno 2026 – A 50 años del golpe cívico-militarhttps://www.pharmaradar360.com/article/dhsc-public-appointments-2026-to-2027-92f3e9c4047ba1dcPharma Surgeen2026-07-01T11:59:25.000ZDHSC public appointments: 2026 to 2027https://www.pharmaradar360.com/article/vaccine-update-issue-372-june-2026-menb-special-60599e6b4e31904aPharma Surgeen2026-07-01T11:59:00.000ZVaccine update: issue 372, June 2026, MenB specialhttps://www.pharmaradar360.com/article/fda-approves-orca-bio-s-t-cell-therapy-for-blood-cancer-patients-da86d1a31fc39d1fPharma Surgeen2026-07-01T11:40:34.000ZFDA approves Orca Bio’s T cell therapy for blood cancer patientshttps://www.pharmaradar360.com/article/harpreet-singh-supporting-biotech-through-clinical-and-regulatory-strategy-83aed7325848f90cPharma Surgeen2026-07-01T11:31:44.000ZHarpreet Singh: Supporting Biotech Through Clinical and Regulatory Strategyhttps://www.pharmaradar360.com/article/while-you-watched-chips-biotech-nearly-doubled-here-s-why-d6cece50a9f35a8aPharma Surgeen2026-07-01T11:30:33.000ZWhile You Watched Chips, Biotech Nearly Doubled — Here's Whyhttps://www.pharmaradar360.com/article/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listin-5e9441f806996141Pharma Surgeen2026-07-01T11:30:00.000ZAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)https://www.pharmaradar360.com/article/new-medical-devices-and-appliances-database-emddb-launches-next-week-20a3c512317e4165Pharma Surgeen2026-07-01T11:24:01.000ZNew Medical Devices and Appliances Database (EMDDB) launches next weekhttps://www.pharmaradar360.com/article/circle-u-universite-paris-cite-is-recruiting-for-its-new-democracy-chair-de1bad9a83576c23Pharma Surgeen2026-07-01T11:16:02.000ZCircle U.: Université Paris Cité is recruiting for its new ‘Democracy’ chairhttps://www.pharmaradar360.com/article/medical-journal-retracts-tavneos-pivotal-paper-amid-wider-regulatory-clampdown-488ee88452b0e749Pharma Surgeen2026-07-01T11:07:48.000ZMedical journal retracts Tavneos pivotal paper amid wider regulatory clampdownhttps://www.pharmaradar360.com/article/prac-juni-2026-herziening-afgerond-van-veiligheidssignaal-over-valproaat-en-verw-9c15f77ecd083172Pharma Surgeen2026-07-01T11:06:59.000ZPRAC juni 2026: herziening afgerond van veiligheidssignaal over valproaat en verwante stoffen en aanbeveling voor gezondheidszorgbeoefenaars met nieuwe veiligheidsgegevens over chikungunya-vaccin Ixchiqhttps://www.pharmaradar360.com/article/sompo-c465f6e6bb9e5003Pharma Surgeen2026-07-01T11:00:00.000Z「SOMPOサステナビリティ・インデックス」の構成銘柄に選定https://www.pharmaradar360.com/article/inverclyde-public-holiday-reminder-e98fb11105e32977Pharma Surgeen2026-07-01T10:50:02.000ZInverclyde public holiday reminderhttps://www.pharmaradar360.com/article/kemri-and-aref-explore-expanded-collaboration-to-strengthen-research-capacity-in-eb50338965ccb97ePharma Surgeen2026-07-01T10:36:27.000ZKEMRI and AREF Explore Expanded Collaboration to Strengthen Research Capacity in Africahttps://www.pharmaradar360.com/article/lonza-expands-manufacturing-capacity-for-hpapi-and-adc-payload-linkers-9f08463e6065aebdPharma Surgeen2026-07-01T10:34:30.000ZLonza expands manufacturing capacity for HPAPI and ADC payload-linkershttps://www.pharmaradar360.com/article/new-transatlantic-research-network-athena-advances-mechanistic-insights-and-tran-61bb4e4f270fad00Pharma Surgeen2026-07-01T10:20:42.000ZNew transatlantic research network ATHENA advances mechanistic insights and translational applications in cardiovascular diseasehttps://www.pharmaradar360.com/article/prof-mesias-alfeus-s-vision-brings-global-finance-congress-to-africa-9e6ee115bd5ab49bPharma Surgeen2026-07-01T10:19:03.000ZProf Mesias Alfeus’s vision brings global finance congress to Africahttps://www.pharmaradar360.com/article/telum-raises-18-million-euros-for-hospital-pneumonia-program-6ca41f650918e4c2Pharma Surgeen2026-07-01T10:15:07.000ZTelum raises 18 million euros for hospital pneumonia programhttps://www.pharmaradar360.com/article/alzecure-lands-2-2-billion-neurorestore-licensing-deal-72c21c4570dad3dcPharma Surgeen2026-07-01T10:15:07.000ZAlzeCure lands $2.2 billion NeuroRestore licensing dealhttps://www.pharmaradar360.com/article/kemri-takes-centre-stage-as-act-chik-project-kicks-off-to-advance-chikungunya-va-09d8bf5508af2f0bPharma Surgeen2026-07-01T10:13:16.000ZKEMRI Takes Centre Stage as ACT-CHIK Project Kicks Off to Advance Chikungunya Vaccine Research in Africahttps://www.pharmaradar360.com/article/new-drug-data-makes-this-french-biotech-stock-a-buy-says-jefferies-1dc8dc0b61b6a13bPharma Surgeen2026-07-01T10:12:10.000ZNew drug data makes this French biotech stock a buy, says Jefferieshttps://www.pharmaradar360.com/article/lilly-and-regeneron-amongst-first-incumbents-to-fda-s-fast-track-facility-scheme-adf9737b74e87ef3Pharma Surgeen2026-07-01T10:09:45.000ZLilly and Regeneron amongst first incumbents to FDA’s fast-track facility schemehttps://www.pharmaradar360.com/article/goldenwell-biotech-gwll-q1-2026-shows-loss-and-going-concern-warning-df74ecaf53929bfcPharma Surgeen2026-07-01T10:09:20.000ZGoldenwell Biotech (GWLL) Q1 2026 shows loss and going concern warninghttps://www.pharmaradar360.com/article/goldenwell-biotech-otcqb-gwll-flags-going-concern-risk-in-2025-cf13ce25a3877f74Pharma Surgeen2026-07-01T10:09:20.000ZGoldenwell Biotech (OTCQB: GWLL) flags going concern risk in 2025https://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-is-up-6-7-after-21-revenue-jump-on-injectable-d-47cc861d6fc42d91Pharma Surgeen2026-07-01T10:08:19.000ZWest Pharmaceutical Services (WST) Is Up 6.7% After 21% Revenue Jump On Injectable Demand - Has The Bull Case Changed?https://www.pharmaradar360.com/article/centogene-apac-office-official-opening-ceremony-in-taiwan-5e7c2f33ff3d28adPharma Surgeen2026-07-01T10:07:11.000ZCENTOGENE APAC Office Official Opening Ceremony in Taiwanhttps://www.pharmaradar360.com/article/act-brief-tavneos-trial-integrity-issues-selective-safety-data-regulatory-pathwa-d14bf0a3f9a7f024Pharma Surgeen2026-07-01T10:06:40.000ZACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launchhttps://www.pharmaradar360.com/article/goldenwell-biotech-inc-fy-2025-revenue-55-net-loss-296471-eps-2-99-10-k-summary-ea57dfc53f124f66Pharma Surgeen2026-07-01T10:05:01.000ZGOLDENWELL BIOTECH, INC. FY 2025: Revenue $55 Net loss $296471 EPS $(2.99) — 10-K Summaryhttps://www.pharmaradar360.com/article/goldenwell-biotech-inc-1q-2026-revenue-0-eps-0-00018-10-q-summary-71268ca281a05e1bPharma Surgeen2026-07-01T10:01:01.000ZGOLDENWELL BIOTECH, INC. 1Q 2026: Revenue $0 EPS $(0.00018) — 10-Q Summaryhttps://www.pharmaradar360.com/article/how-a-chinese-heart-could-get-us-blood-pumping-despite-biotech-decoupling-801466b4a21cfe26Pharma Surgeen2026-07-01T10:00:11.000ZHow a ‘Chinese heart’ could get US blood pumping despite biotech decouplinghttps://www.pharmaradar360.com/article/lab-created-spudcell-marks-stunning-step-toward-building-life-from-scratch-9966f2435db7f991Pharma Surgeen2026-07-01T10:00:00.000ZLab-created ‘SpudCell’ marks ‘stunning’ step toward building life from scratchhttps://www.pharmaradar360.com/article/abivax-expands-obefazimod-safety-data-ahead-of-fda-filing-57029d6faeceac41Pharma Surgeen2026-07-01T09:59:59.000ZAbivax expands obefazimod safety data ahead of FDA filinghttps://www.pharmaradar360.com/article/kapihan-session-convenes-media-and-biotech-experts-for-a-dialogue-on-agricultura-377588e82dc66952Pharma Surgeen2026-07-01T09:53:43.000ZKapihan Session Convenes Media and Biotech Experts for a Dialogue on Agricultural Biotechnologyhttps://www.pharmaradar360.com/article/4708-cabdf63b6a2f0e25Pharma Surgeen2026-07-01T09:37:59.000Z4708https://www.pharmaradar360.com/article/4707-8003cbbb2de7d330Pharma Surgeen2026-07-01T09:36:44.000Z4707https://www.pharmaradar360.com/article/europe-s-best-ai-literacy-initiative-for-education-comes-from-finland-cc45e34c3ae40328Pharma Surgeen2026-07-01T09:34:42.000ZEurope’s best AI literacy initiative for education comes from Finlandhttps://www.pharmaradar360.com/article/4706-4c09c5bdd99442bcPharma Surgeen2026-07-01T09:34:38.000Z4706https://www.pharmaradar360.com/article/the-quiet-winner-behind-the-ai-trade-biotech-s-2026-comeback-a723f4aa062804f0Pharma Surgeen2026-07-01T09:34:14.000ZThe Quiet Winner Behind the AI Trade: Biotech’s 2026 Comebackhttps://www.pharmaradar360.com/article/sicherung-des-erfahrungswissens-in-der-pflege-94aa1750c95dd382Pharma Surgeen2026-07-01T09:32:47.000ZSicherung des Erfahrungswissens in der Pflegehttps://www.pharmaradar360.com/article/cough-cold-877c2faa981b330bPharma Surgeen2026-07-01T09:25:44.000ZCough & coldhttps://www.pharmaradar360.com/article/pain-management-74e41bd83ec19eadPharma Surgeen2026-07-01T09:25:44.000ZPain managementhttps://www.pharmaradar360.com/article/neurology-a58b635c9e0a6948Pharma Surgeen2026-07-01T09:25:44.000ZNeurologyhttps://www.pharmaradar360.com/article/cardiometabolic-71013c17e503dc1fPharma Surgeen2026-07-01T09:25:44.000ZCardiometabolichttps://www.pharmaradar360.com/article/intim-health-eca7c77944742754Pharma Surgeen2026-07-01T09:25:44.000ZIntim healthhttps://www.pharmaradar360.com/article/gastroenterology-7cd4a508c75ee48ePharma Surgeen2026-07-01T09:25:44.000ZGastroenterologyhttps://www.pharmaradar360.com/article/skin-care-9aa94a454f51adf8Pharma Surgeen2026-07-01T09:25:44.000ZSkin carehttps://www.pharmaradar360.com/article/antibiotics-and-antiseptics-fa9bdda42fd922adPharma Surgeen2026-07-01T09:25:44.000ZAntibiotics and antisepticshttps://www.pharmaradar360.com/article/drugs-for-allergy-59a97128d8db45f3Pharma Surgeen2026-07-01T09:25:44.000ZDrugs for Allergyhttps://www.pharmaradar360.com/article/a86aeaacc0794fc2Pharma Surgeen2026-07-01T09:25:44.000ZПрепарати від застуди та температуриhttps://www.pharmaradar360.com/article/67fd799badde67b2Pharma Surgeen2026-07-01T09:25:44.000ZПрепарати від болю та запаленняhttps://www.pharmaradar360.com/article/7e50fbf1abda0ef5Pharma Surgeen2026-07-01T09:25:44.000ZНеврологічні препаратиhttps://www.pharmaradar360.com/article/711130ed8801dad3Pharma Surgeen2026-07-01T09:25:44.000ZКардіометаболічні препаратиhttps://www.pharmaradar360.com/article/093eccbbf126368dPharma Surgeen2026-07-01T09:25:44.000ZПрепарати для інтимного здоров'яhttps://www.pharmaradar360.com/article/4b0e5cd187e5d81bPharma Surgeen2026-07-01T09:25:44.000ZПрепарати для застосування у хірургії